Sino BiopharmaceuticalSBMFF 62 Return-on-Tangible-Equity is -7.85% as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.59 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,197 Biotechnology companies, Sino Biopharmaceutical ranks better than 85.3% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sino Biopharmaceutical's annualized net income for the quarter that ended in Dec. 2025 was $-297 Mil. Sino Biopharmaceutical's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $3,783 Mil. Therefore, Sino Biopharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -7.85%.
The historical rank and industry rank for Sino Biopharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:
SBMFF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.33 Med: 21.58 Max: 94.49
Current: 8.5
During the past 13 years, Sino Biopharmaceutical's highest Return-on-Tangible-Equity was 94.49%. The lowest was 8.33%. And the median was 21.58%.
SBMFF's Return-on-Tangible-Equity is ranked better than 85.3% of 1197
companies
in the Biotechnology industry
Industry Median: -42.4
vs SBMFF: 8.50
Sino Biopharmaceutical (OTCPK:SBMFF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sino Biopharmaceutical Return-on-Tangible-Equity Related Terms
Sino Biopharmaceutical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical Return-on-Tangible-Equity Chart
SBMFF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -7.85% mean?
Sino Biopharmaceutical (SBMFF) has a Return-on-Tangible-Equity of -7.85% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sino Biopharmaceutical and its competitors. Over the past decade, Sino Biopharmaceutical's Return-on-Tangible-Equity has ranged from 8.33 to 94.49. According to the industry distribution chart, Sino Biopharmaceutical ranks #176 out of 1197 companies in the Biotechnology industry, placing it in the top 14.7%.
Is Sino Biopharmaceutical's Return-on-Tangible-Equity too high?
Sino Biopharmaceutical's current Return-on-Tangible-Equity is -7.85%. Over the past 10 years, this metric has ranged from a low of 8.33 to a high of 94.49. Based on the distribution chart, Sino Biopharmaceutical ranks #176 out of 1197 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #176 out of 1197 companies for Return-on-Tangible-Equity. This places Sino Biopharmaceutical in the top 15% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own Return-on-Tangible-Equity has ranged from 8.33 to 94.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Return-on-Tangible-Equity is -7.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.59, compared to a current price of $0.64 — trading 8% above its estimated fair value. The current Return-on-Tangible-Equity is -7.85%. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Return-on-Tangible-Equity is -7.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $0.64 is trading 8% above its estimated GF Value™ of $0.59.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Return-on-Tangible-Equity: -7.85%
GF Value™: $0.59 vs. price of $0.64 (8% above fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
